Ganga Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
GANGAPHARM
Pharmaceuticals
Screen Ganga Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Market Cap
₹9.90 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
0.88
EPS (TTM)
₹0.16
Dividend Yield
-
Debt to Equity
0.20
52W High
-
52W Low
-
Operating Margin
-2.00%
Profit Margin
-
Revenue (TTM)
₹2.00
EBITDA
-
Net Income
-
Total Assets
₹9.00
Total Equity
₹7.00
Ganga Pharmaceuticals Share Price History - Stock Screener Chart
Screen GANGAPHARM historical share price movements with interactive charts. Analyze price trends and patterns.
Ganga Pharmaceuticals Company Profile - Fundamental Screener
Screen Ganga Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GANGAPHARM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE615T01017
Ganga Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen GANGAPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 7 |
| Current Assets | 7 | 6 | 5 | 5 | 5 | 4 | 4 | 5 | 4 | 5 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Liabilities | ||||||||||
| Total Liabilities | 9 | 9 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 7 |
| Current Liabilities | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 7 | 7 | 6 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Share Capital | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves & Surplus | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Screen GANGAPHARM income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 3 |
| Expenses | 1 | 3 | 3 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 2 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Operating Profit % | -2.00% | -4.00% | 2.00% | 0.00% | 2.00% | 1.00% | 13.00% | 12.00% | 11.00% | 10.00% | 12.00% | 9.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS | 0.10 | 0.16 | 0.11 | 0.10 | 0.09 | 0.05 | 0.46 | 0.46 | 0.23 | 0.18 | 0.12 | 0.00 |
Ganga Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen GANGAPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Investing Activities | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | -1 |
| Financing Activities | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Screen GANGAPHARM shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Jul | 2025-Sept | 2024-Mar | 2024-Sept | 2023-Mar | 2023-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 56.02% | 50.91% | 50.91% | 50.91% | 56.02% | 56.02% | 66.71% | 66.71% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 35.07% | 35.46% | 35.46% | 35.32% | 35.40% | 35.23% | 31.91% | 31.91% |
| Other Holding | 8.91% | 13.63% | 13.63% | 13.77% | 8.58% | 8.75% | 1.38% | 1.38% |
| Shareholder Count | 368 | 367 | 367 | 366 | 363 | 365 | 356 | 359 |
Ganga Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen GANGAPHARM dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Ganga Pharmaceuticals Index Membership - Market Screener Classification
Screen GANGAPHARM by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Ganga Pharmaceuticals Market Events Screener - Corporate Actions
Screen GANGAPHARM market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -20.67% | ||
| Annual General Meeting | NA | 0.00% | ||
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 0.00% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 0.00% |
| 2024-11-08 | 2024-11-08 | Quarterly Result Announcement | NA | 0.00% |
| 2024-01-04 | 2024-01-04 | Extraordinary General Meeting | NA | 88.72% |
Ganga Pharmaceuticals Competitors Screener - Peer Comparison
Screen GANGAPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 415,589 | 40.16 | 54,729 | 9.71% | 10,980 | 46.18 |
| Divis Laboratories | 174,227 | 69.16 | 9,712 | 18.67% | 2,191 | 53.62 |
| Torrent Pharmaceuticals | 129,841 | 60.40 | 11,539 | 6.99% | 1,911 | 62.04 |
| Cipla | 120,824 | 22.30 | 28,410 | 7.12% | 5,291 | 44.91 |
| Dr Reddys Laboratories | 105,679 | 18.66 | 33,741 | 16.73% | 5,725 | 60.09 |
| Lupin | 96,266 | 22.21 | 22,910 | 13.74% | 3,306 | 60.88 |
| Zydus Life Science | 92,599 | 18.57 | 23,511 | 18.55% | 4,615 | 47.29 |
| Mankind Pharma | 91,203 | 51.90 | 12,744 | 20.90% | 2,007 | 53.62 |
| Aurobindo Pharma | 70,742 | 20.66 | 32,346 | 9.43% | 3,484 | 57.50 |
| Alkem Laboratories | 66,179 | 27.75 | 13,458 | 3.70% | 2,216 | 47.48 |
Ganga Pharmaceuticals Company Announcements - News Screener
Screen GANGAPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-11-07 | Statement Of Deviation Or Variation Pursuant To Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-07 | Statement Of Deviation Or Variation Pursuant To Regulation 32 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-11-07 | Un-Audited Financial Results Of The Company For The Half Year Ended On September 30 2025. | View |
| 2025-11-07 | Board Meeting Outcome for Held On Friday November 07 2025 | View |
| 2025-11-03 | Board Meeting Intimation for To Consider And Approve The Unaudited Financial Results Of The Company For The Half Year Ended On September 30 2025 | View |
| 2025-10-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-22 | Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-09-20 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-20 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-19 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-08-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-26 | Dispatch Of Letter To Shareholders | View |
| 2025-08-26 | Reg. 34 (1) Annual Report. | View |
| 2025-08-26 | Notice Of The 36Th Annual General Meeting Of The Company | View |
| 2025-08-20 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | View |
| 2025-08-20 | Corporate Action - Fixes Book Closure For (AGM) | View |
| 2025-08-20 | Intimation For 36Th Annual General Meeting Scheduled To Be Held On Saturday September 20 2025. | View |
| 2025-08-20 | Board Meeting Outcome for Held On Wednesday August 20 2025 | View |
| 2025-08-05 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |